Batavia Biosciences has expanded its viral vector process development facilities in the U.S. and its GMP clean room facilities in the Netherlands.   Enhanced capabilities at the company’s R&D facility in Medford, MA allows Batavia to extend its existing service portfolio in the U.S., adding complete preclinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development s...